Anika Therapeutics (ANIK) Tops Q3 EPS by 12c

Go back to Anika Therapeutics (ANIK) Tops Q3 EPS by 12c

Anika Reports Third Quarter 2016 Financial Results

October 26, 2016 4:06 PM EDT

Worldwide Orthobiologics Revenue Increases 10% Year-over-Year

Diluted Earnings Per Share Increases to $0.59

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary... More